Stock Analysis on Net

IQVIA Holdings Inc. (NYSE:IQV)

This company has been moved to the archive! The financial data has not been updated since November 1, 2023.

Enterprise Value to FCFF (EV/FCFF)

Microsoft Excel

Free Cash Flow to The Firm (FCFF)

IQVIA Holdings Inc., FCFF calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net income attributable to IQVIA Holdings Inc. 1,091 966 279 191 259
Net income attributable to non-controlling interests 5 29 36 25
Net noncash charges 1,253 1,291 1,192 1,171 1,076
Changes in operating assets and liabilities (84) 680 459 19 (106)
Net cash provided by operating activities 2,260 2,942 1,959 1,417 1,254
Interest paid, net, net of tax1 307 293 322 282 326
Acquisition of property, equipment and software (674) (640) (616) (582) (459)
Right-of-use assets obtained in exchange for finance lease obligations (54) (44) (119)
Free cash flow to the firm (FCFF) 1,839 2,551 1,546 1,117 1,121

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Item Description The company
FCFF Free cash flow to the firm is the cash flow available to the IQVIA Holdings Inc. suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. IQVIA Holdings Inc. FCFF increased from 2020 to 2021 but then slightly decreased from 2021 to 2022 not reaching 2020 level.

Interest Paid, Net of Tax

IQVIA Holdings Inc., interest paid, net of tax calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Effective Income Tax Rate (EITR)
EITR1 19.08% 14.45% 19.30% 32.95% 17.99%
Interest Paid, Net of Tax
Interest paid, net, before tax 379 343 399 421 398
Less: Interest paid, net, tax2 72 50 77 139 72
Interest paid, net, net of tax 307 293 322 282 326

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 See details »

2 2022 Calculation
Interest paid, net, tax = Interest paid, net × EITR
= 379 × 19.08% = 72


Enterprise Value to FCFF Ratio, Current

IQVIA Holdings Inc., current EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in millions)
Enterprise value (EV) 44,519
Free cash flow to the firm (FCFF) 1,839
Valuation Ratio
EV/FCFF 24.21
Benchmarks
EV/FCFF, Competitors1
AbbVie Inc. 16.76
Amgen Inc. 24.08
Bristol-Myers Squibb Co. 10.12
Danaher Corp. 35.15
Eli Lilly & Co. 680.69
Gilead Sciences Inc. 16.17
Johnson & Johnson 19.45
Merck & Co. Inc. 30.21
Moderna Inc.
Pfizer Inc. 32.17
Regeneron Pharmaceuticals Inc. 20.69
Thermo Fisher Scientific Inc. 28.90
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences 20.23
EV/FCFF, Industry
Health Care 19.79

Based on: 10-K (reporting date: 2022-12-31).

1 Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.


Enterprise Value to FCFF Ratio, Historical

IQVIA Holdings Inc., historical EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Enterprise value (EV)1 53,832 55,061 47,884 42,823 38,267
Free cash flow to the firm (FCFF)2 1,839 2,551 1,546 1,117 1,121
Valuation Ratio
EV/FCFF3 29.28 21.58 30.97 38.33 34.12
Benchmarks
EV/FCFF, Competitors4
AbbVie Inc. 12.15 13.18 13.95 11.60
Amgen Inc. 16.01 15.82 14.51 16.05
Bristol-Myers Squibb Co. 13.87 10.52 11.63 23.39
Danaher Corp. 25.74 28.25 30.66 37.11
Eli Lilly & Co. 59.14 38.37 39.01 36.26
Gilead Sciences Inc. 13.58 8.42 13.60 9.78
Johnson & Johnson 23.80 21.25 20.75 19.31
Merck & Co. Inc. 19.09 23.27 34.12 20.46
Moderna Inc. 11.76 3.86 29.20
Pfizer Inc. 9.15 8.40 21.74 19.44
Regeneron Pharmaceuticals Inc. 17.96 9.81 25.74 19.54
Thermo Fisher Scientific Inc. 31.61 33.14 26.14 28.88
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences 17.82 15.03 20.02 19.33
EV/FCFF, Industry
Health Care 17.63 16.41 17.93 18.26

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 See details »

2 See details »

3 2022 Calculation
EV/FCFF = EV ÷ FCFF
= 53,832 ÷ 1,839 = 29.28

4 Click competitor name to see calculations.

Valuation ratio Description The company
EV/FCFF Enterprise value to free cash flow to the firm is whole company valuation indicator. IQVIA Holdings Inc. EV/FCFF ratio decreased from 2020 to 2021 but then increased from 2021 to 2022 not reaching 2020 level.